Evidence map›Paper›PMID 24527359›Full record

ReviewAdvances in wound care2013

Translational Bioinformatics Approaches to Drug Development.

Ben Readhead, Joel Dudley

Abstract readReview
In one paragraph

Review in Advances in wound care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. MeSHDD: Literature-based drug-drug similarity for drug repositioning.Journal of the American Medical Informatics Association : JAMIA · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ben ReadheadCenter for Biomedical Informatics, Icahn School of Medicine at Mount Sinai , New York, New York. ; Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai , New York, New York.
Joel DudleyCenter for Biomedical Informatics, Icahn School of Medicine at Mount Sinai , New York, New York. ; Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai , New York, New York. ; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai , New York, New York.
Icahn School of Medicine at Mount Sinai · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

significanceA majority of therapeutic interventions occur late in the pathological process, when treatment outcome can be less predictable and effective, highlighting the need for new precise and preventive therapeutic development strategies that consider genomic and environmental context. Translational bioinformatics is well positioned to contribute to the many challenges inherent in bridging this gap between our current reactive methods of healthcare delivery and the intent of RECENT ADVANCES: A variety of powerful informatics methods for organizing and leveraging the vast wealth of available molecular measurements available for a broad range of disease contexts have recently emerged. These include methods for data driven disease classification, drug repositioning, identification of disease biomarkers, and the creation of disease network models, each with significant impacts on drug development approaches. CRITICAL ISSUES: An important bottleneck in the application of bioinformatics methods in translational research is the lack of investigators who are versed in both biomedical domains and informatics. Efforts to nurture both sets of competencies within individuals and to increase interfield visibility will help to accelerate the adoption and increased application of bioinformatics in translational research. FUTURE DIRECTIONS: It is possible to construct predictive, multiscale network models of disease by integrating genotype, gene expression, clinical traits, and other multiscale measures using causal network inference methods. This can enable the identification of the "key drivers" of pathology, which may represent novel therapeutic targets or biomarker candidates that play a more direct role in the etiology of disease.

Identifiers

PMID24527359
PMCPMC3817001
OpenAlexW2106726007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.